Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

被引：0
|
作者：
Cao, Z. Alexander [1 ]
Pinzon-Ortiz, Maria [1 ]
Chen, Yan [1 ]
Li, Xiaoyan [1 ]
Beltran, Pedro J. [2 ]
Gansert, Jennifer [2 ]
Peters, Malte [3 ]
Schlegel, Robert [1 ]
Schumacher, Karl M. [3 ]
Huang, Alan [1 ]
机构：
[1] Novartis, Cambridge, MA USA
[2] Amgen Inc, Thousand Oaks, CA USA
[3] Novartis, Basel, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3683
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab.
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Chen, Yan
    Li, Xiaoyan
    Beltran, Pedro J.
    Gansert, Jennifer L.
    Peters, Malte
    Schlegel, Robert
    Schumacher, Karl Maria
    Huang, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel
    Huang, Alan
    Fritsch, Christine
    Wilson, Christopher
    Reddy, Anupama
    Liu, Manway
    Lehar, Joseph
    Quadt, Cornelia
    Hofmann, Francesco
    Schlegel, Robert
    CANCER RESEARCH, 2012, 72
  • [3] The role of BYL719 in PIK3CA-mutated cervical cancer
    Bogani, G.
    Bini, M.
    Raspagliesi, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S389 - S389
  • [4] Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER -positive (ER plus ) metastatic breast cancer (MBC)
    Juric, D.
    Argiles, G.
    Burns, H. A.
    Gonzalez-Angulo, A. M.
    Saura, C.
    Quadt, C.
    Douglas, M.
    Demanse, D.
    De Buck, S.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [5] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
    Bogani, Giorgio
    Chiappa, Valentina
    Bini, Marta
    Ronzulli, Dominique
    Indini, Alice
    Conca, Elena
    Raspagliesi, Francesco
    TUMORI JOURNAL, 2023, 109 (02): : 244 - 248
  • [6] BYL719 (ALPELISIB) FOR THE TREATMENT OF PIK3CA-MUTATED, RECURRENT/ADVANCED CERVICAL CANCER
    Bogani, G.
    Bini, M.
    Ronzulli, D.
    Raspagliesi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A12 - A12
  • [7] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
    Bogani, G.
    Indini, A.
    Bini, M.
    Raspagliesi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S754 - S754
  • [8] Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
    Munster, Pamela
    Elkabets, Moshe
    Gilbert, Jill
    Razak, Albiruni R. Abdul
    Ahn, Myung-Ju
    Yen, Chia-Jui
    Lee, Se-Hoon
    Wang, Hung-Ming
    van Herpen, Carla
    Lim, Wan-Teck
    Demanse, David
    Pal, Rupam Ranjan
    Huang, Alan
    Sheng, Qing
    Lambertini, Chiara
    Peters, Malte
    Coughlin, Christina
    Scaltriti, Maurizio
    Baselga, Jose
    Blumenschein, George
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [9] Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
    Chen, Li
    Yang, Liu
    Yao, Ling
    Kuang, Xia-Ying
    Zuo, Wen-Jia
    Li, Shan
    Qiao, Feng
    Liu, Yi-Rong
    Cao, Zhi-Gang
    Zhou, Shu-Ling
    Zhou, Xiao-Yan
    Yang, Wen-Tao
    Shi, Jin-Xiu
    Huang, Wei
    Hu, Xin
    Shao, Zhi-Ming
    NATURE COMMUNICATIONS, 2018, 9
  • [10] Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
    Li Chen
    Liu Yang
    Ling Yao
    Xia-Ying Kuang
    Wen-Jia Zuo
    Shan Li
    Feng Qiao
    Yi-Rong Liu
    Zhi-Gang Cao
    Shu-Ling Zhou
    Xiao-Yan Zhou
    Wen-Tao Yang
    Jin-Xiu Shi
    Wei Huang
    Xin Hu
    Zhi-Ming Shao
    Nature Communications, 9
12345